{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T14:55:43Z","timestamp":1792248943297,"version":"4.4.0"},"reference-count":190,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Juvenile idiopathic inflammatory myopathy (JIIM) is a rare systemic autoimmune disease characterized by skeletal muscle weakness with or without a skin rash. Juvenile dermatomyositis (JDM) is the most common subtype of JIIM, accounting for 80% of JIIM. Recent studies identified several myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs). Each MSA or MAA is associated with distinct clinical features and outcomes, although there are several differences in the prevalence of MSA\/MAA and autoantibody\u2013phenotype relationships between age and ethnic groups. Histopathological studies have revealed critical roles of type I interferons and vasculopathy in the development of JDM. Serological classification mostly corresponds to clinicopathological classification. Novel therapeutic agents, such as biologics and Janus kinase inhibitors (JAKi), have been developed; however, to date, there is a lack of high-level evidence. As advances in treatment have reduced the mortality rate of JIIM, recent studies have focused on medium- and long-term outcomes. However, rapidly progressive interstitial lung disease (RP-ILD) remains a major cause of death in anti-melanoma differentiation gene 5 autoantibody-positive JDM. Early diagnosis and intervention using a multi-drug regimen is critical for the treatment of RP-ILD. Rituximab and JAKi may reduce mortality in patients with JDM-associated RP-ILD refractory to conventional therapy.<\/jats:p>","DOI":"10.3390\/children11091046","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T06:19:01Z","timestamp":1724739541000},"page":"1046","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Advances in Juvenile Dermatomyositis: Pathophysiology, Diagnosis, Treatment and Interstitial Lung Diseases\u2014A Narrative Review"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4956-4010","authenticated-orcid":false,"given":"Ichiro","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Center for Pediatric Allergy and Rheumatology, KKR Sapporo Medical Center, 3-40 Hiragishi 1-6, Toyohira-ku, Sapporo 060-0931, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41584-023-00967-9","article-title":"Juvenile idiopathic inflammatory myositis: An update on pathophysiology and clinical care","volume":"19","author":"Papadopoulou","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/joim.12444","article-title":"The juvenile idiopathic inflammatory myopathies: Pathogenesis, clinical and autoantibody phenotypes, and outcomes","volume":"280","author":"Rider","year":"2016","journal-title":"J. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MD.0b013e31827f264d","article-title":"The clinical phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Shah","year":"2013","journal-title":"Medicine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/art.11122","article-title":"US incidence of juvenile dermatomyositis, 1995\u20131998: Results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry","volume":"49","author":"Mendez","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/rheumatology\/34.8.732","article-title":"The incidence of juvenile dermatomyositis: Results from a nation-wide study","volume":"34","author":"Symmons","year":"1995","journal-title":"Br. J. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort","volume":"84","author":"Tansley","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","article-title":"The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Rider","year":"2013","journal-title":"Medicine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14397595.2018.1452353","article-title":"Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies","volume":"29","author":"Ueki","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1093\/rheumatology\/keab108","article-title":"Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: Multicentre study","volume":"60","author":"Yamasaki","year":"2021","journal-title":"Rheumatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jpeds.2010.11.033","article-title":"Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis","volume":"158","author":"Kobayashi","year":"2011","journal-title":"J. Pediatr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/rheumatology\/keu385","article-title":"Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis","volume":"54","author":"Kobayashi","year":"2015","journal-title":"Rheumatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/14397595.2020.1718866","article-title":"Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-update","volume":"30","author":"Kobayashi","year":"2020","journal-title":"Mod. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12969-023-00903-x","article-title":"Nailfold capillary density in 140 untreated children with juvenile dermatomyositis: An indicator of disease activity","volume":"21","author":"Pachman","year":"2023","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Pinotti, C.S., Cannon, L., Dvergsten, J.A., and Wu, E.Y. (2023). Calcinosis in juvenile dermatomyositis: Updates on pathogenesis and treatment. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1155839"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/MD.0b013e31816bc604","article-title":"Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity","volume":"87","author":"Bingham","year":"2008","journal-title":"Medicine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1365-2133.2007.08055.x","article-title":"A systematic review of juvenile-onset clinically amyopathic dermatomyositis","volume":"157","author":"Gerami","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/rheumatology\/keab518","article-title":"Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash","volume":"61","author":"Ichimura","year":"2022","journal-title":"Rheumatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/art.23012","article-title":"International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: A tool for potential use in clinical trials","volume":"57","author":"Wedderburn","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul. Disord."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/WCO.0000000000000740","article-title":"Classification of idiopathic inflammatory myopathies: Pathology perspectives","volume":"32","author":"Tanboon","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-mediated necrotizing myopathy: Clinical features and pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Wang, C.H., and Liang, W.C. (2023). Pediatric immune-mediated necrotizing myopathy. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1123380"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/art.37985","article-title":"Brief report: Ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis","volume":"65","author":"Shah","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/rheumatology\/kex162","article-title":"Environmental factors associated with disease flare in juvenile and adult dermatomyositis","volume":"56","author":"Mamyrova","year":"2017","journal-title":"Rheumatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/art.21068","article-title":"History of infection before the onset of juvenile dermatomyositis: Results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry","volume":"53","author":"Pachman","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Sassetti, C., Borrelli, C., Mazuy, M., Turrini, I., Rigante, D., and Esposito, S. (2024). The relationship between infectious agents and juvenile dermatomyositis: A narrative update from the pediatric perspective. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1377952"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/gene.2015.28","article-title":"Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes","volume":"16","author":"Miller","year":"2015","journal-title":"Genes Immun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1136\/annrheumdis-2015-208119","article-title":"Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups","volume":"75","author":"Rothwell","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1093\/hmg\/ddac019","article-title":"Association with HLA-DR\u03b21 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis","volume":"31","author":"Deakin","year":"2022","journal-title":"Hum. Mol. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1002\/art.38137","article-title":"Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders","volume":"65","author":"Miller","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Chen, S., Wang, Q., Wu, Z., Li, Y., Li, P., Sun, F., Zheng, W., Wu, Q., Wu, C., and Deng, C. (2014). Genetic association study of TNFAIP3, IFIH1, IRF5 polymorphisms with polymyositis\/dermatomyositis in Chinese Han population. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0110044"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1046\/j.1523-1747.2002.19608.x","article-title":"Mannose binding lectin (MBL) polymorphisms associated with low MBL production in patients with dermatomyositis","volume":"119","author":"Werth","year":"2002","journal-title":"J. Investig. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3233\/JND-230168","article-title":"Contribution of complement, microangiopathy and inflammation in idiopathic inflammatory myopathies","volume":"11","author":"Honda","year":"2024","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/art.41639","article-title":"The vasculopathy of juvenile dermatomyositis: Endothelial injury, hypercoagulability, and increased arterial stiffness","volume":"73","author":"Papadopoulou","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3899\/jrheum.181275","article-title":"Endothelial activation markers as disease activity and damage measures in juvenile dermatomyositis","volume":"47","author":"Kishi","year":"2020","journal-title":"J. Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11926-022-01076-4","article-title":"Update on biomarkers of vasculopathy in juvenile and adult myositis","volume":"24","author":"McLellan","year":"2022","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3899\/jrheum.2022-0827","article-title":"Type I interferons in autoimmunity: Implications in clinical phenotypes and treatment response","volume":"50","author":"Londe","year":"2023","journal-title":"J. Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrrheum.2018.31","article-title":"Type I interferon in rheumatic diseases","volume":"14","author":"Muskardin","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ana.410160206","article-title":"Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells","volume":"16","author":"Arahata","year":"1984","journal-title":"Ann. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ana.410160207","article-title":"Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis","volume":"16","author":"Engel","year":"1984","journal-title":"Ann. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/art.22558","article-title":"Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis","volume":"56","author":"Vallejo","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/nan.12519","article-title":"Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis","volume":"45","author":"Uruha","year":"2019","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/nan.12551","article-title":"Absence of sarcoplasmic myxovirus resistance protein A (MxA) expression in antisynthetase syndrome in a cohort of 194 cases","volume":"45","author":"Inoue","year":"2019","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_47","first-page":"194","article-title":"Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies","volume":"59","author":"Wilkinson","year":"2020","journal-title":"Rheumatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/art.24555","article-title":"Elevated serum interferon-alpha activity in juvenile dermatomyositis: Associations with disease activity at diagnosis and after thirty-six months of therapy","volume":"60","author":"Niewold","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1084\/jem.20101664","article-title":"Type I interferon: Friend or foe?","volume":"207","author":"Trinchieri","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1442-200x.2001.01367.x","article-title":"Elevated serum levels of soluble interleukin-2 receptor in juvenile dermatomyositis","volume":"43","author":"Kobayashi","year":"2001","journal-title":"Pediatr. Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/art.21103","article-title":"Activation of the endoplasmic reticulum stress response in autoimmune myositis: Potential role in muscle fiber damage and dysfunction","volume":"52","author":"Nagaraju","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.ircmb.2019.10.004","article-title":"Type I interferons and endoplasmic reticulum stress in health and disease","volume":"350","author":"Sprooten","year":"2020","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/BOR.0000000000000212","article-title":"Understanding the origin of non-immune cell-mediated weakness in the idiopathic inflammatory myopathies-potential role of ER stress pathways","volume":"27","author":"Lightfoot","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: An important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J. Intern. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/rheumatology\/keaa429","article-title":"Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America","volume":"60","author":"Mamyrova","year":"2021","journal-title":"Rheumatology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s12098-021-03680-1","article-title":"Autoantibody profile of children with juvenile dermatomyositis","volume":"88","author":"Sharma","year":"2021","journal-title":"Indian J. Pediatr."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.semarthrit.2020.10.007","article-title":"Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis","volume":"51","author":"Sag","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_58","first-page":"966","article-title":"The analysis of clinical phenotypes and autoantibodies in juvenile dermatomyositis","volume":"58","author":"Li","year":"2020","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12969-021-00574-6","article-title":"Myositis autoantibodies in a racially diverse population of children with idiopathic inflammatory myopathies","volume":"19","author":"Perron","year":"2021","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar4600","article-title":"Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: A prospective cohort study","volume":"16","author":"Tansley","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/rheumatology\/kez525","article-title":"Anti-MDA5 juvenile idiopathic inflammatory myopathy: A specific subgroup defined by differentially enhanced interferon-\u03b1 signaling","volume":"59","author":"Melki","year":"2020","journal-title":"Rheumatology"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Wang, K., Zhao, J., Wu, W., Xu, W., Sun, S., Chen, Z., Fu, Y., Guo, L., Du, H., and Ye, S. (2021). RNA-containing immune complexes formed by anti-melanoma differentiation associated gene 5 autoantibody are potent inducers of IFN-\u03b1. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.743704"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s10067-015-2935-9","article-title":"Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis\/dermatomyositis","volume":"34","author":"Chen","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"103416","DOI":"10.1016\/j.autrev.2023.103416","article-title":"Lung involvement in juvenile idiopathic inflammatory myopathy: A systematic review","volume":"22","author":"Marrani","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/acr.22212","article-title":"Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies","volume":"66","author":"Huber","year":"2014","journal-title":"Arthritis Care Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/rheumatology\/key190","article-title":"Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis","volume":"57","author":"Mamyrova","year":"2018","journal-title":"Rheumatology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/art.42768","article-title":"Clinical features and immunogenetic risk factors associated with additional autoantibodies in anti-transcriptional intermediary factor 1\u03b3 juvenile-onset dermatomyositis","volume":"76","author":"Sherman","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: New and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jdermsci.2016.09.013","article-title":"Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis","volume":"84","author":"Fujimoto","year":"2016","journal-title":"J. Dermatol. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ana.24902","article-title":"Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies","volume":"81","author":"Allenbach","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.23113","article-title":"Association of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies with DRB1*07:01 and severe myositis in juvenile myositis patients","volume":"69","author":"Kishi","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/rheumatology\/kew386","article-title":"Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies","volume":"56","author":"Liang","year":"2017","journal-title":"Rheumatology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2018-215004","article-title":"Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis","volume":"78","author":"Sabbagh","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1093\/rheumatology\/keab846","article-title":"Association of anti-HSC70 autoantibodies with cutaneous ulceration and severe disease in juvenile dermatomyositis","volume":"61","author":"Karasawa","year":"2022","journal-title":"Rheumatology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/annrheumdis-2017-212436","article-title":"Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis","volume":"77","author":"Yeker","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_77","first-page":"668","article-title":"Classification criteria for polymyositis and dermatomyositis","volume":"22","author":"Tanimoto","year":"1995","journal-title":"J. Rheumatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.semarthrit.2019.12.001","article-title":"Performance of the new EULAR\/ACR classification criteria for idiopathic inflammatory myopathies (IIM) in a large monocentric IIM cohort","volume":"50","author":"Barsotti","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/annrheumdis-2019-215488","article-title":"First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)\/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort","volume":"79","author":"Jinnin","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/rheumatology\/keaa274","article-title":"External validation of the EULAR\/ACR idiopathic inflammatory myopathies classification criteria with a Japanese paediatric cohort","volume":"60","author":"Yamazaki","year":"2021","journal-title":"Rheumatology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"688","DOI":"10.55563\/clinexprheumatol\/4tz6ci","article-title":"Validation of the EULAR\/ACR 2017 idiopathic inflammatory myopathy classification criteria in juvenile dermatomyositis patients","volume":"39","author":"Sag","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/1756-185X.13605","article-title":"Validation of 2017 classification criteria for adult and juvenile idiopathic inflammatory myopathies proposed by EULAR\/ACR in Chinese patients","volume":"22","author":"Zhang","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1136\/annrheumdis-2020-217568","article-title":"External validation of EULAR\/ACR classification criteria for idiopathic inflammatory myopathies","volume":"81","author":"Luu","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jpeds.2005.10.032","article-title":"Duration of illness is an important variable for untreated children with juvenile dermatomyositis","volume":"148","author":"Pachman","year":"2006","journal-title":"J. Pediatr."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Enders","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1529-0131(200003)43:3<541::AID-ANR9>3.0.CO;2-T","article-title":"Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis","volume":"43","author":"Huber","year":"2000","journal-title":"Arthritis Rheum."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.semarthrit.2018.03.016","article-title":"Medications received by patients with juvenile dermatomyositis","volume":"48","author":"Kishi","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","article-title":"British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy","volume":"61","author":"Oldroyd","year":"2022","journal-title":"Rheumatology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/rheumatology\/keg040","article-title":"Interstitial lung disease associated with juvenile dermatomyositis: Clinical features and efficacy of cyclosporin A","volume":"42","author":"Kobayashi","year":"2003","journal-title":"Rheumatology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/rheumatology\/keaa436","article-title":"Risk factors associated with Pneumocystis jirovecii pneumonia in juvenile myositis in North America","volume":"60","author":"Sabbagh","year":"2021","journal-title":"Rheumatology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3109\/14397595.2014.969916","article-title":"Pediatric Rheumatology Association of Japan (PRAJ) recommendation for vaccination in pediatric rheumatic diseases","volume":"25","author":"Kobayashi","year":"2015","journal-title":"Mod. Rheum."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3899\/jrheum.160688","article-title":"Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash","volume":"44","author":"Huber","year":"2017","journal-title":"J. Rheumatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/09546630310018509","article-title":"Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: A pilot study","volume":"15","author":"Hollar","year":"2004","journal-title":"J. Dermatol. Treat."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/acr.20071","article-title":"Protocols for the initial treatment of moderately severe juvenile dermatomyositis: Results of a Children\u2019s Arthritis and Rheumatology Research Alliance Consensus Conference","volume":"62","author":"Huber","year":"2010","journal-title":"Arthritis Care Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3899\/jrheum.190494","article-title":"Pilot Study of the Juvenile Dermatomyositis Consensus Treatment Plans: A CARRA Registry Study","volume":"48","author":"Liu","year":"2021","journal-title":"J. Rheumatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/acr.20695","article-title":"Consensus treatments for moderate juvenile dermatomyositis: Beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference","volume":"64","author":"Huber","year":"2012","journal-title":"Arthritis Care Res"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12969-019-0326-5","article-title":"The PRINTO evidence-based proposal for glucocorticoids tapering\/discontinuation in new onset juvenile dermatomyositis patients","volume":"17","author":"Giancane","year":"2019","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","article-title":"Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: A randomized trial","volume":"387","author":"Ruperto","year":"2016","journal-title":"Lancet"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00431-004-1497-7","article-title":"Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A","volume":"163","author":"Yamada","year":"2004","journal-title":"Eur. J. Pediatr."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s10067-008-0973-2","article-title":"Treatment of refractory juvenile dermatomyositis with tacrolimus","volume":"27","author":"Hassan","year":"2008","journal-title":"Clin. Rheumatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/rheumatology\/keh082","article-title":"Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety","volume":"43","author":"Riley","year":"2004","journal-title":"Rheumatology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/art.40418","article-title":"Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modeling","volume":"70","author":"Deakin","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12969-022-00785-5","article-title":"Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance","volume":"21","author":"Sherman","year":"2023","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/acr.20269","article-title":"Mycophenolate mofetil: A possible therapeutic agent for children with juvenile dermatomyositis","volume":"62","author":"Morgan","year":"2010","journal-title":"Arthritis Care Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3109\/s10165-011-0489-5","article-title":"Mycophenolate mofetil therapy for juvenile dermatomyositis with immune thrombocytopenic purpura","volume":"22","author":"Ogimi","year":"2012","journal-title":"Mod. Rheumatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00296-010-1653-5","article-title":"Mycophenolate mofetil in juvenile dermatomyositis: A case series","volume":"32","author":"Dagher","year":"2012","journal-title":"Rheumatol. Int."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"SI163","DOI":"10.1093\/rheumatology\/keac404","article-title":"Experience with the use of mycophenolate mofetil in juvenile idiopathic inflammatory myopathies","volume":"62","author":"Varnier","year":"2023","journal-title":"Rheumatology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1136\/ard.2011.153718","article-title":"Efficacy of intravenous Ig therapy in juvenile dermatomyositis","volume":"70","author":"Lam","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1542\/peds.2007-1218","article-title":"Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: Adverse reactions are associated with immunoglobulin A content","volume":"121","author":"Manlhiot","year":"2008","journal-title":"Pediatrics"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"J. Clin. Investig."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12969-017-0174-0","article-title":"Biologic therapies for refractory juvenile dermatomyositis: Five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America","volume":"15","author":"Spencer","year":"2017","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1002\/art.22856","article-title":"Rituximab for the treatment of juvenile dermatomyositis: A report of four pediatric patients","volume":"56","author":"Cooper","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3899\/jrheum.101321","article-title":"Safety and efficacy of rituximab in severe juvenile dermatomyositis: Results from 9 patients from the French Autoimmunity and Rituximab registry","volume":"38","author":"Decaluwe","year":"2011","journal-title":"J. Rheumatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"S798","DOI":"10.1097\/RHU.0000000000001460","article-title":"Concurrent treatment with rituximab and plasma exchange for rapidly progressive interstitial lung disease complicating anti-MDA5 antibody-positive juvenile dermatomyositis","volume":"27","author":"Shimizu","year":"2021","journal-title":"J. Clin. Rheumatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12969-021-00595-1","article-title":"Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: A case report and literature review","volume":"19","author":"Yeung","year":"2021","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12969-022-00723-5","article-title":"Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: A case report and literature review","volume":"20","author":"Nishi","year":"2022","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3899\/jrheum.2023-0544","article-title":"Clinical improvement in early onset interstitial lung disease using rituximab in children with antimelanoma differentiation-associated dene 5-positive juvenile dermatomyositis","volume":"51","author":"Peskin","year":"2023","journal-title":"J. Rheumatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","article-title":"Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab","volume":"56","author":"Aggarwal","year":"2017","journal-title":"Rheumatology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"663","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/rheumatology\/kew213","article-title":"Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients","volume":"55","author":"Nagaraju","year":"2016","journal-title":"Rheumatology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/rheumatology\/ken074","article-title":"Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis","volume":"47","author":"Riley","year":"2008","journal-title":"Rheumatology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13075-020-02164-5","article-title":"Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients","volume":"22","author":"Deakin","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/acr.22198","article-title":"Pilot study of etanercept in patients with refractory juvenile dermatomyositis","volume":"66","author":"Ferguson","year":"2014","journal-title":"Arthritis Care Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12969-023-00941-5","article-title":"Local injection of infliximab into calcinosis lesions in patients with juvenile dermatomyositis (JDM): A clinical trial","volume":"22","author":"Shiari","year":"2024","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10067-023-06740-3","article-title":"Biologic drugs in the treatment of juvenile dermatomyositis: A literature review","volume":"43","author":"Sener","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jpeds.2011.11.057","article-title":"Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis","volume":"160","author":"Arabshahi","year":"2012","journal-title":"J. Pediatr."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/art.42450","article-title":"Improvement in disease activity in refractory juvenile dermatomyositis following abatacept therapy","volume":"75","author":"Curiel","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jdcr.2023.10.023","article-title":"Refractory dermatomyositis responsive to anifrolumab","volume":"43","author":"Ang","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jamadermatol.2023.4744","article-title":"Rapid improvement in recalcitrant cutaneous juvenile dermatomyositis with anifrolumab treatment","volume":"160","author":"Shaw","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","article-title":"A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-\u03b1 monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients","volume":"73","author":"Higgs","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/rheumatology\/ket413","article-title":"Suppression of soluble T cell-associated proteins by an anti-interferon-\u03b1 monoclonal antibody in adult patients with dermatomyositis or polymyositis","volume":"53","author":"Guo","year":"2014","journal-title":"Rheumatology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signaling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12969-021-00637-8","article-title":"JAK inhibitors: A potential treatment for JDM in the context of the role of interferon-driven pathology","volume":"19","author":"Deakin","year":"2021","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"152426","DOI":"10.1016\/j.semarthrit.2024.152426","article-title":"Treatment with janus kinase inhibitors in juvenile dermatomyositis: A review of the literature","volume":"66","author":"Sener","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1093\/brain\/awy255","article-title":"A child with severe juvenile dermatomyositis treated with ruxolitinib","volume":"141","author":"Aeschlimann","year":"2018","journal-title":"Brain"},{"key":"ref_139","first-page":"e15960","article-title":"Juvenile dermatomyositis-associated calcinosis successfully treated with combined immunosuppressive, bisphosphonate, oral baricitinib and physical therapy","volume":"3","author":"Perez","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_140","first-page":"402","article-title":"Efficacy of Janus kinase inhibitor baricitinib in the treatment of refractory juvenile dermatomyositis complicated by calcinosis","volume":"41","author":"Mastrolia","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1093\/brain\/awz005","article-title":"Janus kinase 1\/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis","volume":"142","author":"Papadopoulou","year":"2019","journal-title":"Brain"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1093\/rheumatology\/keaa360","article-title":"A striking treatment option for recalcitrant calcinosis in juvenile dermatomyositis: Tofacitinib citrate","volume":"59","author":"Demir","year":"2020","journal-title":"Rheumatology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.12998\/wjcc.v10.i11.3579","article-title":"Anti-nuclear matrix protein 2+ juvenile dermatomyositis with severe skin ulcer and infection: A case report and literature review","volume":"10","author":"Wang","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/1756-185X.14258","article-title":"Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease","volume":"25","author":"Mopur","year":"2022","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/brain\/awz293","article-title":"Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib","volume":"142","author":"Sabbagh","year":"2019","journal-title":"Brain"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12969-022-00675-w","article-title":"Progressive, refractory macrophage activation syndrome as the initial presentation of anti-MDA5 antibody positive juvenile dermatomyositis: A case report and literature review","volume":"20","author":"Stewart","year":"2022","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/1756-185X.14630","article-title":"Cardiac involvement in a case of juvenile dermatomyositis with positive anti-melanoma differentiation associated protein 5 antibody","volume":"26","author":"Kaplan","year":"2023","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/ard-2023-223919","article-title":"Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients","volume":"82","author":"Xue","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e252592","DOI":"10.1136\/bcr-2022-252592","article-title":"Cyclophosphamide-induced liver injury during treatment of interstitial lung disease in juvenile dermatomyositis","volume":"16","author":"Zhang","year":"2023","journal-title":"BMJ Case Rep."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Wang, Z., Zheng, Q., Xuan, W., Xu, X., Lu, M., Wu, J., Zou, L., Xu, Y., and Xu, X. (2022). Short-term effectiveness of baricitinib in children with refractory and\/or severe juvenile dermatomyositis. Front. Pediatr., 10.","DOI":"10.3389\/fped.2022.962585"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/keac399","article-title":"Long-term follow-up of Janus-kinase inhibitor and novel active disease biomarker in juvenile dermatomyositis","volume":"62","author":"Huang","year":"2023","journal-title":"Rheumatology"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"S480","DOI":"10.1097\/RHU.0000000000001191","article-title":"Polymyxin-B hemoperfusion as a novel treatment for rapidly progressive interstitial lung disease in a pediatric patient diagnosed with anti-MDA5 juvenile dermatomyositis","volume":"27","author":"Mrosak","year":"2021","journal-title":"J. Clin. Rheumatol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJM199205213262102","article-title":"Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis","volume":"326","author":"Miller","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell therapy in autoimmune disease\u2014A case series with follow-up","volume":"390","author":"Taubmann","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T Cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"ref_156","first-page":"69","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"51","author":"Chung","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"ATS\/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"e003150","DOI":"10.1136\/rmdopen-2023-003150","article-title":"Clinical, radiological and pathological features of anti-MDA5 antibody-associated interstitial lung disease","volume":"9","author":"Chen","year":"2023","journal-title":"RMD Open"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: What progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Fujisawa, T., Hozumi, H., Kono, M., Enomoto, N., Hashimoto, D., Nakamura, Y., Inui, N., Yokomura, K., Koshimizu, N., and Toyoshima, M. (2014). Prognostic factors for myositis-associated interstitial lung disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0098824"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"\u201cERS\/ATS Task Force on Undifferentiated Forms of CTD-ILD\u201d. An official European Respiratory Society\/American Thoracic Society research statement: Interstitial pneumonia with autoimmune features","volume":"46","author":"Fischer","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Xia, J., Jiang, G., Jin, T., Shen, Q., Ma, Y., Wang, L., and Qian, L. (2021). Respiratory symptoms as initial manifestations of interstitial lung disease in clinically amyopathic juvenile dermatomyositis: A case report with literature review. BMC Pediatr., 21.","DOI":"10.1186\/s12887-021-02958-9"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/rheumatology\/40.5.588","article-title":"Interstitial pneumonitis and air leakage in juvenile dermatomyositis","volume":"40","author":"Bahabri","year":"2001","journal-title":"Rheumatology"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jpeds.2004.09.023","article-title":"Fatal acute fibrinous and organizing pneumonia in a child with juvenile dermatomyositis","volume":"146","author":"Prahalad","year":"2005","journal-title":"J. Pediatr."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/s10165-007-0610-y","article-title":"Juvenile dermatomyositis: Clinical characteristics and the relatively high risk of interstitial lung disease","volume":"17","author":"Morinishi","year":"2007","journal-title":"Mod. Rheumatol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1684\/ejd.2010.0846","article-title":"Fatal interstitial pneumonia in juvenile dermatomyositis","volume":"20","author":"Nagai","year":"2010","journal-title":"Eur. J. Dermatol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1442-200X.2009.02946.x","article-title":"Juvenile amyopathic dermatomyositis complicated by progressive interstitial pneumonia","volume":"52","author":"Abe","year":"2010","journal-title":"Pediatr. Int."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3899\/jrheum.101220","article-title":"Anti-CADM-140 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and cardiac involvement","volume":"38","author":"Sakurai","year":"2011","journal-title":"J. Rheumatol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12969-021-00532-2","article-title":"Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease-a case report","volume":"19","author":"Kishi","year":"2021","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"110117","DOI":"10.1080\/25785826.2024.2336687","article-title":"Successful treatment with tofacitinib for anti-melanoma differentiation-associated gene 5 antibody-positive juvenile dermatomyositis: Case reports and review of the literature","volume":"47","author":"Yamazaki","year":"2024","journal-title":"Immunol. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1067\/mpd.2001.110324","article-title":"KL-6 is a potential marker for interstitial lung disease associated with juvenile dermatomyositis","volume":"138","author":"Kobayashi","year":"2001","journal-title":"J. Pediatr."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1080\/14397595.2016.1231102","article-title":"Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis","volume":"27","author":"Sato","year":"2017","journal-title":"Mod. Rheumatol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/s10165-012-0647-4","article-title":"Clinical analysis of 50 children with juvenile dermatomyositis","volume":"23","author":"Kishi","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3899\/jrheum.100608","article-title":"Autoantibody to PL-12 (Anti-Alanyl-tRNA synthetase) in an African American girl with juvenile dermatomyositis and resolution of interstitial lung disease","volume":"38","author":"Vega","year":"2011","journal-title":"J. Rheumatol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/ppul.22742","article-title":"The lung is involved in juvenile dermatomyositis","volume":"48","author":"Pouessel","year":"2013","journal-title":"Pediatr. Pulmonol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/ard.2010.131433","article-title":"Pulmonary outcome in juvenile dermatomyositis: A case-control study","volume":"70","author":"Sanner","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/rheumatology\/ket380","article-title":"Pulmonary function and autoantibodies in a long-term follow-up of juvenile dermatomyositis patients","volume":"53","author":"Mathiesen","year":"2014","journal-title":"Rheumatology"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13075-016-1214-8","article-title":"Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease","volume":"19","author":"Enomoto","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3899\/jrheum.170997","article-title":"Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases","volume":"45","author":"Kawasumi","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10067-017-3799-y","article-title":"Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis","volume":"37","author":"Peng","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.22293","article-title":"Restricted T cell receptor BV gene usage in the lungs and muscles of patients with idiopathic inflammatory myopathies","volume":"56","author":"Englund","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1046\/j.1440-1843.1999.00179.x","article-title":"Flowcytometric analysis of bronchoalveolar lavage fluid cells in polymyositis\/dermatomyositis with interstitial pneumonia","volume":"4","author":"Kourakata","year":"1999","journal-title":"Respirology"},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Ikeda, S., Arita, M., Morita, M., Ikeo, S., Ito, A., Tokioka, F., Noyama, M., Misaki, K., Notohara, K., and Ishida, T. (2015). Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: To lump or split?. BMC Pulm. Med., 15.","DOI":"10.1186\/s12890-015-0154-4"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1007\/s00296-011-2323-y","article-title":"Anti-MDA5 antibody is associated with A\/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis","volume":"32","author":"Chen","year":"2012","journal-title":"Rheumatol. Int."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","article-title":"Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease","volume":"53","author":"Gono","year":"2014","journal-title":"Rheumatology"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12931-023-02362-0","article-title":"Enhanced immune complex formation in the lungs of patients with dermatomyositis","volume":"24","author":"Zaizen","year":"2023","journal-title":"Respir. Res."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.3899\/jrheum.140977","article-title":"Increased serum B cell activating factor and a proliferation-inducing ligand are associated with interstitial lung disease in patients with juvenile dermatomyositis","volume":"42","author":"Kobayashi","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/rheumatology\/kez394","article-title":"Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis\/dermatomyositis: A single-arm clinical trial","volume":"59","author":"Takada","year":"2020","journal-title":"Rheumatology"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3899\/jrheum.2023-0371","article-title":"Long-term prognosis of antimelanoma differentiation-associated gene 5-positive dermatomyositis with interstitial lung disease","volume":"50","author":"Sasai","year":"2023","journal-title":"J. Rheumatol."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/11\/9\/1046\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:43:21Z","timestamp":1760111001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/11\/9\/1046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":190,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["children11091046"],"URL":"https:\/\/doi.org\/10.3390\/children11091046","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]}}}